McKesson Specialty Pharmacy — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$370,022	1
2023	Research	$769,205	2
2022	Research	$702,321	3
2020	Research	$11,119,264	4
2019	Research	$653,680	2

Breakdown

Who paid Research payments · program years 2019–2024

Pfizer Inc. $5,911,407 1 payment
AstraZeneca Pharmaceuticals LP $4,981,092 2 payments
AbbVie, Inc. $1,841,548 6 payments
Sanofi US Services Inc. $880,443 3 payments

Studies the money was for Research payments · program years 2019–2024

A Randomized Phase II Trial of Salvage Radiotherapy With Standard VS Enhanced Androgen Deprivation Therapy With Enzalutamide in Patients With Postprostatectomy Psa Recurrences With Aggressive Disease Features $5,911,407 1 payment
Concept of Osimertinib Combined with Stereotactic Ablative Radiotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer $4,626,953 1 payment
Myeloma-Developing Regimens Using Genomics (My-DRUG): Genomics guided multi-arm trial of targeted agents alone or in combination with a backbone regimen $1,471,526 5 payments
An Exploratory Randomized Phase II Multicenter Trial of Abiraterone Acetate with or without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer $880,443 3 payments
Myeloma-Developing Regimens Using Genomics (My-DRUG) Genomics guided multi-arm trial of targeted agents alone or in combination with a backbone regimen $370,022 1 payment
A phase II study of Olaparib and Durvalumab in Men with Castration Sensitive Biochemically Recurrent Non Metastatic and Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair $354,140 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.